The supplement-arbitrage position built on nicotinamide mononucleotide in China is closed. The capital recreating that position in Singapore and Australia is pricing a regulatory tolerance the NMPA already withdrew.

China's NMPA restricted NMN commercial sale in 2023, reclassifying it as a new food ingredient requiring pre-market approval that operates in practice as a drug-development submission: pharmacokinetic data, a safety package, review by the NMPA's Center for Drug Evaluation. The restriction arrived before any Phase 2 RCT with an aging primary endpoint had been completed anywhere. The largest published human trial was Yoshino et al. (Science, 2021, n=25, postmenopausal women, primary endpoint skeletal muscle insulin sensitivity, a metabolic measure with no pre-specified aging outcome). Mainland NMN platforms, operating in the supplement retail channel with no IND submissions to the Center for Drug Evaluation, had priced exits on consumer-revenue multiples. The capital was priced as a supplement. The NMPA read it as a drug.

HSA's Health Products Regulation Group and TGA's Office of Complementary Medicines both currently permit NMN sale under complementary-medicine frameworks designed for vitamins and botanical extracts. Both frameworks pre-date the human pharmacology literature on NAD+ repletion at commercial doses. Capital raised through Singapore longevity-clinic operators and Australian supplement distributors in 2025 and Q1 2026 has reproduced the same structure: revenue multiples, no IND pipeline, clinical-adjacent claims framed as consumer-health language to stay within HSA's and TGA's complementary-product thresholds. Any reclassification submission for NMN in Australia would route to TGA's Advisory Committee on Medicines, not the Office of Complementary Medicines. No NMN sponsor has filed one.